Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Parsol 1789 safety/effectiveness with some Category I sunscreens established -- FDA.

This article was originally published in The Tan Sheet

Executive Summary

PARSOL 1789 SAFETY/EFFECTIVENESS WITH CATEGORY I SUNSCREENS ESTABLISHED, FDA concluded in a May 9 letter to King & Spalding attorney Edward Basile. In response to the March 2, 1993 citizen petition filed by Basile on behalf on Givaudan-Roure, FDA said it would allow use of UVA blocker Parsol 1789 (avobenzone) 2%-3% in combination with some Category I sunscreen ingredients. The petition is now being handled by Givaudan-Roure sister company Hoffmann-La Roche.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS085446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel